Abstract
Costs of Extended Use of the Immune Checkpoint Inhibitors in First-line Non-Small Cell Lung Cancer
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have